Biogen’s closely watched Phase III results for its amyloid-targeting therapy aducanumab in the treatment of patients with early Alzheimer’s disease, presented on 5 December at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego, did not answer a big outstanding question: Can the drug win US Food and Drug Administration approval?
The company presented a complex dataset, including results only for patients treated with the highest dose of aducanumab based on a fourth and final clinical trial protocol change that allowed for patients with the ApoE4 gene to be titrated up to the highest dose
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?